Log In
BCIQ
Print this Print this
 

KN035

  Manage Alerts
Collapse Summary General Information
Company Suzhou Alphamab Co. Ltd.
DescriptionPD-L1 single domain antibody fused to an Fc
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced and metastatic solid tumors
Regulatory Designation
Partner3DMed

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today